Natixis Catalent, Inc. Transaction History

Natixis

$17.6 Billion
Q3 2024

A detailed history of Natixis transactions in Catalent, Inc. stock. As of the latest transaction made, Natixis holds 1,537,787 shares of CTLT stock, worth $97.6 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares

1,537,787

Previous 266,292 477.48%

Holding current value

$97.6 Million

Previous $15 Million 522.07%

% of portfolio

0.53%

Previous 0.09%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$56.16 - $60.96 $71.4 Million - $77.5 Million	1,271,495 Added 477.48%	1,537,787 $93.1 Million
Q2 2024 Aug 13, 2024	BUY	$53.58 - $57.02 $960,260 - $1.02 Million	17,922 Added 7.22%	266,292 $15 Million
Q1 2024 May 13, 2024	SELL	$42.56 - $59.82 $170,495 - $239,638	-4,006 Reduced 1.59%	248,370 $14 Million
Q4 2023 Feb 13, 2024	BUY	$32.18 - $46.57 $7.78 Million - $11.3 Million	241,616 Added 2245.5%	252,376 $11.3 Million
Q3 2023 Nov 14, 2023	SELL	$44.2 - $50.2 $8 Million - $9.08 Million	-180,914 Reduced 94.39%	10,760 $489,000
Q2 2023 Aug 11, 2023	BUY	$31.86 - $67.26 $6.11 Million - $12.9 Million	191,674 New	191,674 $8.31 Million
Q4 2022 Feb 13, 2023	BUY	$41.39 - $81.0 $289,730 - $567,000	7,000 Added 21.7%	39,256 $1.77 Million
Q3 2022 Nov 14, 2022	BUY	$72.36 - $113.1 $225,184 - $351,967	3,112 Added 10.68%	32,256 $2.34 Million
Q2 2022 Aug 12, 2022	SELL	$87.2 - $114.05 $675,102 - $882,975	-7,742 Reduced 20.99%	29,144 $3.13 Million
Q1 2022 May 13, 2022	BUY	$94.19 - $124.49 $3.2 Million - $4.23 Million	33,993 Added 1175.01%	36,886 $4.09 Million
Q4 2021 Feb 14, 2022	SELL	$119.57 - $139.07 $337,306 - $392,316	-2,821 Reduced 49.37%	2,893 $371,000
Q3 2021 Nov 12, 2021	SELL	$109.17 - $142.35 $85,916 - $112,029	-787 Reduced 12.11%	5,714 $760,000
Q2 2021 Aug 13, 2021	SELL	$100.34 - $115.69 $1.11 Million - $1.28 Million	-11,069 Reduced 63.0%	6,501 $703,000
Q1 2021 May 14, 2021	SELL	$101.51 - $125.27 $1.96 Million - $2.41 Million	-19,275 Reduced 52.31%	17,570 $1.85 Million
Q4 2020 Feb 12, 2021	BUY	$85.88 - $105.36 $498,104 - $611,088	5,800 Added 18.68%	36,845 $3.83 Million
Q3 2020 Nov 12, 2020	BUY	$72.74 - $92.5 $934,272 - $1.19 Million	12,844 Added 70.57%	31,045 $2.66 Million
Q2 2020 Aug 13, 2020	BUY	$48.02 - $79.04 $874,012 - $1.44 Million	18,201 New	18,201 $1.33 Million
Q2 2019 Aug 13, 2019	SELL	$39.26 - $54.21 $1.17 Million - $1.61 Million	-29,751 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$29.84 - $43.92 $35,987 - $52,967	-1,206 Reduced 3.9%	29,751 $1.21 Million
Q4 2018 Feb 14, 2019	SELL	$29.95 - $46.34 $390,637 - $604,412	-13,043 Reduced 29.64%	30,957 $965,000
Q3 2018 Nov 14, 2018	SELL	$40.12 - $45.55 $348,081 - $395,191	-8,676 Reduced 16.47%	44,000 $2 Million
Q2 2018 Aug 14, 2018	SELL	$38.72 - $42.52 $6.02 Million - $6.61 Million	-155,391 Reduced 74.68%	52,676 $2.21 Million
Q1 2018 May 15, 2018	BUY	$39.4 - $47.39 $813,925 - $978,982	20,658 Added 11.02%	208,067 $8.54 Million
Q4 2017 Feb 14, 2018	BUY	$37.27 - $43.02 $3.58 Million - $4.13 Million	96,019 Added 105.07%	187,409 $7.7 Million
Q3 2017 Nov 14, 2017	BUY	$33.75 - $41.67 $1.61 Million - $1.98 Million	47,562 Added 108.52%	91,390 $3.65 Million
Q2 2017 Aug 14, 2017	BUY	N/A	43,828	43,828 $1.54 Million

Others Institutions Holding CTLT

# of Institutions

514

Shares Held

149M

Call Options Held

575K

Put Options Held

2.03M

View Full List

About Catalent, Inc.

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

More about CTLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Account